Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Update    symbols : Sls    save search

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
SLS | $1.54 0.0% 1.5M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

life year update sciences financial results
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
Published: 2024-03-26 (Crawled : 12:00) - globenewswire.com
SLS | $1.54 0.0% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 1.92% H: 2.83% C: 0.0%

sls009 positive update topline aml study
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
Published: 2024-03-19 (Crawled : 12:30) - globenewswire.com
SLS | $1.54 0.0% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 6.67% H: 0.89% C: -6.25%

life update sciences
SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET
Published: 2023-12-13 (Crawled : 13:30) - globenewswire.com
SLS | $1.54 0.0% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 0.98% H: 4.85% C: 2.91%

update
SELLAS Provides Business Update and Reports Third Quarter 2023 Financial Results
Published: 2023-11-09 (Crawled : 00:00) - biospace.com/
SLS | $1.54 0.0% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 0.87% H: 0.0% C: -4.21%

business update financial results
SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia
Published: 2023-10-12 (Crawled : 20:00) - globenewswire.com
SLS | $1.54 0.0% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 12.56% H: 11.57% C: 7.44%

life update sciences leukemia trial
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results
Published: 2023-08-10 (Crawled : 20:00) - globenewswire.com
BMY | $49.14 0.43% 0.2% 6.4M twitter stocktwits trandingview |
Health Technology
| | O: 0.39% H: 0.33% C: -0.49%
SLS | $1.54 0.0% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: -0.64% H: 3.85% C: -0.72%

business life update sciences financial results
SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results
Published: 2023-05-11 (Crawled : 20:00) - globenewswire.com
SLS | $1.54 0.0% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: -0.58% H: 0.0% C: -10.59%

business life update sciences financial results
SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
Published: 2023-03-16 (Crawled : 21:00) - globenewswire.com
BMY | $49.14 0.43% 0.2% 6.4M twitter stocktwits trandingview |
Health Technology
| | O: 0.34% H: 0.0% C: -1.19%
SLS | $1.54 0.0% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: -0.72% H: 0.73% C: -1.46%

business life year update sciences financial results
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results
Published: 2022-11-14 (Crawled : 13:00) - globenewswire.com
SLS | $1.54 0.0% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: -31.65% H: 2.89% C: -18.01%

sciences life financial update results
SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia
Published: 2022-11-14 (Crawled : 13:00) - globenewswire.com
SLS | $1.54 0.0% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: -31.65% H: 2.89% C: -18.01%

sciences life leukemia trial update acute myeloid leukemia
SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022
Published: 2022-11-02 (Crawled : 13:00) - biospace.com/
SLS | $1.54 0.0% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: -1.46% H: 2.11% C: -15.82%

sciences life update study
SELLAS Life Sciences to Host Update Call on Phase 3 REGAL Study on November 14, 2022
Published: 2022-10-17 (Crawled : 13:00) - globenewswire.com
SLS | $1.54 0.0% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 3.66% H: 1.64% C: 1.01%

sciences life update study
SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial
Published: 2022-06-27 (Crawled : 14:00) - biospace.com/
SLS | $1.54 0.0% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 1.69% H: 0.0% C: -3.33%

gfh009 ongoing sciences life trial update phase 1
Gainers vs Losers
73% 27%

Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M twitter stocktwits trandingview |

AGBA | $2.5 100.0% 56.6% 200M twitter stocktwits trandingview |
Finance

MLEC | $2.47 76.43% 42.62% 78M twitter stocktwits trandingview |
n/a

NUWE | $0.334 29.96% 40.99% 2.5M twitter stocktwits trandingview |
Manufacturing

EDBL | News | $6.26 66.49% 40.13% 16M twitter stocktwits trandingview |

ATGL | $2.86 46.25% 32.8% 180K twitter stocktwits trandingview |

VIVK | $1.43 33.65% 27.7% 530K twitter stocktwits trandingview |
Professional, Scientific, and T...

MNTS | $0.5 35.69% 26.3% 4.7M twitter stocktwits trandingview |

SDIG A | $3.64 35.32% 26.0% 990K twitter stocktwits trandingview |

PROK | $2.72 33.33% 24.58% 2.6M twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.